

## Special Issue

# Study on Tumor Microenvironment in Lymphoma

### Message from the Guest Editor

The evolution of the tumor microenvironment (TME), which is made up of non-malignant cells and an extracellular matrix, is regarded as an essential component of the processes leading to tumor development and progression. In the case of lymphomas, interactions between tumor cells and the TME have been shown to be crucial for tumor cell survival and proliferation and the evasion of immune responses. This Special Issue will consider the importance of the TME across the diverse spectrum of lymphomas, considering the role of direct cell–cell interactions, as well as the involvement of soluble factors, including cytokines and chemokines. As therapies that target the TME are increasingly being applied, we encourage articles that consider novel targets in the tumor microenvironment or that consider new developments in the field of immune checkpoints.

### Guest Editor

Dr. Paul Gerard Murray

Health Research Institute, School of Medicine, University of Limerick,  
V94 T9PX Limerick, Ireland

### Deadline for manuscript submissions

closed (10 November 2022)



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/73392](https://mdpi.com/si/73392)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)